Skip to content

The Oligonucleotide Therapeutics Society is Pleased to Announce the 2023 Annual Meeting in Barcelona, Spain

Oligonucleotide Therapeutics Society 3 mins read

SAN DIEGO, CA / ACCESSWIRE / June 28, 2023 / The Oligonucleotide Therapeutics Society (OTS) is excited to bring together those in the field of oligonucleotide therapeutics for its 19th Annual Oligo Meeting. Anyone interested in oligonucleotide therapeutics is welcome to join the event, which will be held virtually and in person on Oct. 22-25, 2023, in Barcelona, Spain.

Oligonucleotide Therapeutics Society, Wednesday, June 28, 2023, Press release picture

OTS is an open, nonprofit forum that fosters academic and industry-based research and the development of oligonucleotide therapeutics. At this year's meeting, leaders from across the globe will present alongside students, covering topics ranging from antisense, siRNA, immunostimulatory and aptamer applications, RNA/DNA editing, mRNA therapeutics, and basic RNA research.

This year's keynote speaker will be David Liu, PhD, from the Broad Institute of Harvard and MIT. Liu is known for inventing base editing, a tool for precisely modifying DNA, as well as prime editing, PACE and DNA-templated synthesis - technologies used by thousands of labs worldwide. His many achievements include being elected to the U.S. National Academy of Sciences, the U.S. National Academy of Medicine, and the American Association for the Advancement of Science. Liu has published over 225 papers and is the inventor of over 90 issued U.S. patents.

OTS has the privilege of presenting its Lifetime Achievement Awards, with the 2022 Award going to Sudhir Agrawal, D. Phil, a key player in the discovery and development of RNA therapeutics and the co-inventor of over 400 patents worldwide. As president and founder of ARNAY Sciences LLC, his company's pioneering publications helped establish antisense as a new drug discovery platform and have contributed to critical discoveries in gapmer antisense and exon skipping.

The 2023 Lifetime Achievement Award will be presented to Cy Stein, MD, PhD, who has over three decades of experience treating prostate and genitourinary cancer patients. Throughout his career, Stein has mixed his love for science with his passion for caring for patients and hopes to continue doing so for many years to come. His four decades of scientific research have primarily been dedicated to developing novel anti-cancer drugs.

As the area of oligonucleotide therapeutics continues to thrive and evolve, OTS will continue to support this vital work, with its annual meeting serving as a dialogue and discussion among industry, academia, and health authorities to educate and share their progress. Currently, over 100 oligonucleotide treatments are in development for common and rare conditions, including cancer and Alzheimer's disease, and several have received regulatory approval.

OTS looks forward to seeing attendees either in person or online. In-person registration will be closed at 750 delegates, so early registration is recommended for those wishing to attend in person.

Anyone interested in attending can view more information at or register here.

Media Contact:

Geri Beaty
Phone: (619) 795-9458

Contact Information:

Geri Beaty
Media Contact
(619) 795-9458

SOURCE: Oligonucleotide Therapeutics Society


View source version on

More from this category

  • Biotechnology
  • 01/12/2023
  • 23:07
HanchorBio Inc.

HanchorBio to Present at the ESMO Immuno-Oncology 2023 Annual Congress

SAN FRANCISCO, CA and TAIPEI, TAIWAN / ACCESSWIRE / December 1, 2023 / HanchorBio Inc., a global clinical-stage biotechnology company focusing on the discovery and development of innovative immuno-biomedicines to treat a wide variety of patients suffering from hard-to-treat solid tumors or hematological malignancies, today announced the acceptance of poster presentation at the European Society for Medical Oncology Immuno-Oncology (ESMO-IO) 2023 Annual Congress, taking place in Geneva, Switzerland and online from December 6-8, 2023. Details of the presentation are as follows. The full abstracts will be made available on the ESMO website on Thursday, 30 November 2023 at 00:05 CET.Title:…

  • Biotechnology, Medical Health Aged Care
  • 24/11/2023
  • 13:15
Island Pharmaceuticals

Island Pharmaceuticals doses first cohort in ISLA-101 Single Ascending Dose study

TheSingleAscendingDosestudyisadoseescalationstudy,inwhichthreecohorts ofhealthysubjectswillreceive escalatingdosesofISLA-101 Studywillensurethatadministereddosescansafelyachievebloodconcentrations of ISLA-101 that are predicted to be effective against the dengue virus Datareadoutfromthestudyisexpectedinearly2024 MELBOURNE Australia, 24 November 2023: Australian antiviral drug development company, Island Pharmaceuticals Ltd (ASX: ILA; “Island”; “the Company”) is pleased to announce that it has dosed the first cohort in its Single Ascending Dose (SAD) study for ISLA-101,awell-knowndrugcandidatebeingrepurposedforthepreventionandtreatment of dengue and other mosquito (or vector) borne diseases. The Single Ascending Dose study is being run at Scientia Clinical Research’s clinical trial facilities in Sydney (NSW), Australia, by Contract Research Organisation, Beyond Drug Development (ASX: 25 September 2023). Studyresultsareexpectedinearly2024.Theinsightsgainedfromthisstudywillpavethe wayforoptimisingprotocolsforIsland’s plannedPhase2aPEACHclinicaltrial. CEO of Island…

  • Contains:
  • Biotechnology, Business Company News
  • 23/11/2023
  • 09:34

ASX Hopeful Aegros Appoints Ex-MP As Advisory Committee Chair

Australia’s leading blood fractionator announces a trio of strategic advisor appointments as it lays the groundwork for an IPO Aegros has established a Strategic Advisory Committee (SAC), to provide advice to the Board in preparation for the company’s Initial Public Offering (IPO). The high-profile SAC members will be drawn from experts in their fields, to provide the Board with strategic advice in the lead up to its IPO. This comes after the company signed an agreement with the Queensland Government to build a 1,000,000 litre facility in Springfield, southwest of Brisbane worth over $350 million. 23 November: AEGROS today cemented…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time your distribute with Medianet. Pay per release or save with a subscription.